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Abstract. Different estimation methods for covariance parameters in meta-analyses
can result in conflicting p-values concerning the test of treatment effect. We propose
a valid method to overcome this problem at least partially by introducing a new
estimator for the standard deviation of the common treatment difference.
1. Introduction
Meta-analyses receive increased attention in the recent years. In different application
fields we can make use of the methods of combining information from different studies or
experiments, e.g. for estimating the mean effect of a new treatment by various studies.
Moreover, there exists  methods for a variety of outcome measures.
Recently, there has been a discussion about the comparison of the results of analysing
summary data with the use of individual patient data, see [1] and [2]. However, the same
deficiencies may occur with standard methods for individual patient data as known for
combining summarised data, confer [3],[4],[5],[6]. Here, two examples are used to
illustrate that different estimation methods, implemented in some software packages, can
lead to extreme different results. In this context we propose methods to overcome this
dilemma at least partially. Hence, the tests and confidence intervals for the mean effect will
be less dependent of the estimation method for the parameter of heterogeneity in the
random effects model of meta-analysis .
22. Individual patient data versus summary data
If in meta-analysis one has the opportunity to obtain individual patient data, apart from
the costs, time and effort, one can consider the question, whether analysing individual
patient data gives more precise results than summary data, assuming the suitable quality of
the data.
For the fixed effects model, see below, it can be shown, that the pooled individual
patient data modelled as a two-way ANOVA model without interaction is equivalent to
combining the best linear unbiased estimators from each study, provided that observations
between studies are independent and have a common variance, confer [1]. Recently, it was
stated by [2], that this equivalence is more general. Consequently, it holds also in random
effects models were there exists heterogeneity between studies.
However, in the random effects model we have to estimate covariance parameters. If the
same estimated covariance parameters are used in both data cases, we get the same
estimators for the mean effect, see [2]. So, different results in analysing individual patient
data  or summarised data can be a problem of different estimators in the covariance matrix,
which can be indicated in several software packages as for example in BUGS, S-Plus or
PROC MIXED in SAS, see e.g.[7].
Nonetheless, different estimation methods for the covariance matrix can result in
extreme different decisions concerning the significance of the treatment effect. In the next
section we present a method to overcome this problem.
3. The model
In this context we regard in study i, i=1,...,k, the estimators
$θ i i iy y= −1 2 ,
3where y i1 and y i2 are the mean treatment effect and the mean effect of the control,
respectively, assuming homogeneous variance of the observations in study i. So the
estimated variance of this estimator in a first step is the pooled variance
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where n1i and n2i are the numbers of observations in the treatment and control group,
respectively. In each group we have the (estimated) standard deviations s1i and s2i.
We consider the random effects model for summarised data
$
, ,...,θ θi i ia e i k= + + = 1 ,
where θ is the mean treatment difference, ai is a random effect with mean zero and variance
τ2, and the random error ei has mean zero and variance υ i2 . Hence, a correlation between
observations within studies is assumed. In general, mean effect estimators depend on the
estimation method of the variance component τ2. They are computed by
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Omitting ai in the model and $τ
2 in the estimators, respectively, one gets the
(homogeneous) fixed effects model.
The common estimator of the standard deviation of $θ is given by
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4In the traditional random effects meta-analysis we usually compare the teststatistic
$ $ ( $ )θ σ θ , which involves the method of moments estimator for τ2, also called the
DerSimonian-Laird estimator, see [8], with the (1-α/2)-quantile of the standard normal
distribution. Moreover, there exists proposals to compare the teststatistics with the (1-α/2)-
quantile of the central t-distribution with (k-1) degrees of freedom, confer e.g.[5], and it is
used by SAS PROC MIXED.
Now, we present a new estimator for the standard deviation of $θ based on a method
proposed by [9], which depends merely on the estimation method of τ2. The proposed
estimator of the standard deviation of $θ is given by
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confer [9]. The corresponding teststatistic should also be compared with the (1-α/2)-
quantile of the central t-distribution with (k-1) degrees of freedom. The results of these
methods can be seen in the following examples.
4. Example 1
The author of [7] cites an example of analysing treatment-control differences in a
random effects model of meta-analysis. This example compares specialist multidisciplinary
team care for managing stroke patients with routine management in general medical wards
(from Cochrane Database of Systematic Reviews, 1995). The length of stay was measured
for each patient from nine studies. The data is given in table 1.
5Table 1. Care for stroke patients from nine studies. (SD = standard deviation)
Specialist care Routine management
Study n mean SD n mean SD
1 155 55.0 47.0 156 75.0 64.0
2 31 27.0 7.0 32 29.0 4.0
3 75 64.0 17.0 71 119.0 29.0
4 18 66.0 20.0 18 137.0 48.0
5 8 14.0 8.0 13 18.0 11.0
6 57 19.0 7.0 52 18.0 4.0
7 34 52.0 45.0 33 41.0 34.0
8 110 21.0 16.0 183 31.0 27.0
9 60 30.0 27.0 52 23.0 20.0
For the following table 2, we computed estimators for the heterogeneity variance τ2 with
different methods. We used the traditional random effects meta-analysis with the
DerSimonian-Laird estimator (DL), as well as estimation methods feasible e.g. with PROC
MIXED as Restricted Maximum Likelihood (REML) and Maximum Likelihood (ML).
Moreover, we computed an estimator proposed by Hedges [10] and the fixed effects
estimator (FE). The presented p-values are derived from related t-tests, see section 3.
Table 2. Estimation methods for the heterogeneity variance τ2 and resulting estimators for
the treatment difference, their standard deviations and p-values from t-tests.
Method $τ 2 $ ( $ )θ τ 2 $ ( $ )σ θ p-value $ ( $ )σ θnew pnew-value
DL 218.72 -14.10 5.28 0.0284 8.78 0.1470
REML 685.09 -15.12 8.95 0.1297 9.20 0.1390
ML 596.04 -15.03 8.38 0.1107 9.17 0.1397
HEDGES 771.32 -15.19 9.48 0.1475 9.23 0.1384
FE     0   -3.49 0.78 0.0021 4.29 0.4392
6In the traditional random effects meta-analysis we usually compare the teststatistic with
the (1-α/2)-quantile of the standard normal distribution. Then, we get the p-value p=0.0038
for estimation methods with the DerSimonian-Laird estimator and p<0.0001 in the fixed
effects model.
We see from table 2 that there are differences in the p-values of the standard t-test by
different estimation methods for τ2. If we apply the new estimator for the standard
deviation of $θ we get similar results for the p-values despite of different estimation
methods for τ2 in the random effects model.
5. Example 2
The second example is taken from [3]. They use a data set for testing the effectiveness
of amlodipine in the treatment of angina. Eight randomized controlled trials have compared
the change in work capacity for patients who received either the drug or placebo. The
change in work capacity is the ratio of the exercise time after invention to before for each
patient. The logarithms of the observed changes are assumed to be approximately normally
distributed. The data is given in table 3.
Table 3. Change in work capacity in the treatment of angina.
Amlodipine Placebo
Study n mean variance n mean variance
1 46 0.2316 0.2254 48 -0.0027 0.0007
2 30 0.2811 0.1441 26 0.0270 0.1139
3 75 0.1894 0.1981 72 0.0443 0.4972
4 12 0.0930 0.1389 12 0.2277 0.0488
5 32 0.1622 0.0961 34 0.0056 0.0955
6 31 0.1837 0.1246 31 0.0943 0.1734
7 27 0.6612 0.7060 27 -0.0057 0.9891
8 46 0.1366 0.1211 47 -0.0057 0.1291
7We computed the different estimators for the interesting measures by the various
methods already mentioned in section 4, see table 4.
Table 4. Estimation methods for the heterogeneity variance τ2 and resulting estimators for
the treatment difference, their standard deviations and p-values from t-tests.
Method $τ 2 $ ( $ )θ τ 2 $ ( $ )σ θ p-value $ ( $ )σ θnew pnew-value
DL 0.0066 0.1590 0.0447 0.0093 0.0507 0.0165
REML (SAS) 0 0.1111 0.0305 0.0083 0.0465 0.0496
ML (SAS) 0 0.1068 0.0224 0.0020 0.0476 0.0599
HEDGES 0.0353 0.1654 0.0765 0.0674 0.0632 0.0346
FE 0 0.1624 0.0321 0.0015 0.0427 0.0067
In this example, the estimated heterogeneity variance is very small. For the REML and
the ML estimation method this parameter is estimated by zero. Therefore, one would
expect, that the corresponding estimator for the treatment difference is equal to the fixed
effects estimator, but SAS computes another solution.
If we compare the teststatistics with the (1-α/2)-quantile of the standard normal
distribution, we get the p-value p=0.0004 for estimation methods with the DerSimonian-
Laird estimator and p<0.0001 in the fixed effects model.
The new estimation method results in p-values which are nearly in the same order, while
the common method results in p-values which differ around 30-fold in the values.
6. Concluding remarks
As we see, with the usual methods we can come to quite different conclusions
depending on the chosen method of estimation. Simulation results show, that the proposed
new method equalizes the significance results towards the nominal level. With regard to
section 2, where we considered individual versus summarized data, we have to state, that
also with the individual data case this estimation problem is not yet solved. Moreover, we
8conclude, that the “optimal” estimator for the heterogeneity variance seems not to be found
yet.
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